September 17th 2025
Alteogen received a positive CHMP opinion for EYLUXVI in July 2025
September 4th 2025
Dr Ramtohul's research uses electrophysiologic testing to study the retinal ganglion cells
September 3rd 2025
The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD).
September 1st 2025
Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies
August 28th 2025
Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings
UK audit explores reasons patients skip diabetic retinopathy screenings
Investigators emphasised the need for continued efforts to raise awareness and support patients in attending regular screening
The year in review, with our friends from Modern Retina
Hot topics around the globe, from clinical trials to the solar eclipse
Ophthalmology Times wraps up a year of innovation and insight
Highlights from the year, courtesy of our colleagues at Ophthalmology Times
Wrapping up another year in eye care: 2024 in review
Trending topics and milestone stories from our year in ophthalmology
Finnish researchers report on registry data and changing workload resulting from anti-VEGF therapies
The number of patients with retinal vascular diseases is expected to increase over time due to the aging population and lifestyle changes
See the best of our print edition with the 2024 cover story roundup
Our top 10 print stories highlight the core content concepts we explored this year
EssilorLuxottica announces agreement for acquisition of Espansione Group
Espansione Group's Light Modulation Low-level Light Therapy (LLLT) is used in ophthalmology and dermatology
EMA CHMP issues positive opinion for aflibercept biosimilar, two other candidates from Celltrion
The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)
European Medicines Agency approves faricimab (Vabysmo) 6.0 mg single-dose prefilled syringe
The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion
Investigators report findings on serum inflammatory biomarkers in patients with macular oedema
A retrospective study assessed elevated neutrophil-to-lymphocyte ratios and systemic immune-inflammation index levels in patients with different subtypes of DMO
Diabetic eye disease: Where are we now?
Clinicians must consider redefining the metrics and intention behind functional outcomes, according to experts from the European Association for the Study of Diabetic Eye Complications
Case report: retinopathy associated with the use of hair dye aromatic amines
Presentation closely resembled mitogen-activated extracellular signal-regulated kinase inhibitor–associated retinopathy
Industry updates from Floretina ICOOR 2024
The annual meeting brought fourth announcements and insights from companies in the retina care space
Charles Wykoff, MD, PhD, presents on diabetic retinopathy and "the dream of reperfusion" at Floretina ICOOR 2024
Dr Wykoff addressed the top three questions retina specialists have about retinal non-perfusion
Don’t miss our editorial advisory board members at the Floretina/ICOOR meeting
EAB members from Ophthalmology Times Europe, Ophthalmology Times and Modern Retina are presenting in Florence
New wet AMD therapeutics seek to improve visual outcomes beyond the current standard of care
Breakthrough technologies are raising the ceiling for functional visual outcomes
The Floretina ICOOR meeting begins in Florence, Italy
What to expect from 4 days in the Fortezza de Basso
EMA grants orphan medicinal product designation for OCU410ST (Ocugen)
OCU410ST is indicated for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa and cone-rod dystrophy 3 (CORD3)
Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis
OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases
CHMP issues positive opinion for marketing authorisation of aflibercept biosimilar FYB203 (Formycon)
The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union
US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)
The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration
NHS introduces OCT programme to reduce annual hospital visits for patients with diabetes
Optical coherence tomography will be in all eye care services by October 2025
How a gene-agnostic approach opens doors to new therapeutics
Arun Upadhyay, PhD, discusses new study findings from trials of OCU400 (Ocugen)
US FDA clears investigational new drug application for CRISPR/Cas13 RNA-editing therapy
HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration
Zooming in on geographic atrophy with OCT-based AI
New analysis brings disease progression and therapeutics into focus
Excellence across the board at the 2024 EURETINA congress
This year’s Barcelona meeting brought together award-winning research data and leaders in the retina field
Study: caffeine does not impact retinal vessel density, despite effects on blood pressure
Caffeine has been shown to temporarily increase intraocular pressure and reduce blood flow in critical ocular regions
Ikerian announces commercial expansion of RetinAI Discovery in Europe
New investment from Sanoptis will support Ikerian technology for large-scale, AI-enabled data management
Ocuphire Pharma and Opus Genetics announce merger
The company also announced it will seek a strategic partner to continue development of APX3330, an oral small-molecule inhibitor of Ref-1 for the treatment of non-proliferative diabetic retinopathy.